Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Thumbnail
Date
2019
Dewey
Economie sociale
Sujet
Advanced NSCLC; PD-L1 positive; Cost effectiveness; Pembrolizumab; Economics
JEL code
I.I1.I12; I.I1.I11
Journal issue
Lung Cancer
Volume
127
Publication date
2019
Article pages
44-52
Publisher
Elsevier
DOI
http://dx.doi.org/10.1016/j.lungcan.2018.11.008
URI
https://basepub.dauphine.fr/handle/123456789/19589
Collections
Metadata
Show full item record
Author
Chouaid, Christos
2592 CIC - Biotherapie - CHU Henri Mondor
242232 Service de Pneumologie [CRETEIL - Pneumologie]
Bensimon, Lionel
221125 Merck Sharp & Dohme Corp. [MSD]
Clay, Emilie
221681 Evaluation des systèmes de soins et santé perçue
147877 Creativ-Ceutical France
Millier, Aurélie
147877 Creativ-Ceutical France
203854 Creativ-Ceutical
Levy-Bachelot, Laurie
221125 Merck Sharp & Dohme Corp. [MSD]
Huang, Min
86674 Merck and Co.
Lévy, Pierre
163511 Laboratoire d'Economie de Dauphine [LEDa]
163517 Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
559342 Laboratoire d'Economie de Dauphine [LEDa]
Type
Article accepté pour publication ou publié